Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapeutic Rescue of Steroidogenic Function in Autoimmune Addison's Disease (RAD): Pilot Study
2007-003062-18Phase 4Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in Addison's disease and hypoadrenocorticism, sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoints: Restoration of normal glucocorticoid secretion, Recovery of steroidogenic capacity and 1 more. Started Feb 2008; status: completed.
02
Drugs
rituximab
03
Conditions
Addison's diseasehypoadrenocorticism
Beyond the preview
Go deeper on 2007-003062-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003062-18.